iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie

October 12, 2021
Category: iNFORMED - Blog

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

 

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

 

iCAD will unveil the latest generation of ProFound AI® f... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
ProFound_AI_for_2D_Mammography_Blog_Image.jpg

iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)

October 07, 2021
Category: Press Releases

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

 

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

 

NASHUA, N.H. and PARIS – October 7, 2021 - iCAD, Inc... Continue reading

Tags: press releases

iCAD Releases Next Generation PowerLook Density Assessment Solution

October 06, 2021
Category: iNFORMED - Blog

Dense breasts can make it challenging to detect breast cancer during annual screenings, as overlapping tissue can hide or mimic breast cancer, even with digital breast tomosynthesis (DBT) exams. Breast density assessment has traditionally been determined by the radiologist’s visual assessment, but studies show that these can vary, and clinicians may even disagree with their own assessment year to year.[1] This can be confusing for patients, lead to unnecessary additional imaging, and increase patient and facility costs.

 

Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
Density_Blog_Image-2021.jpg

Next Generation of ProFound AI Risk Offers Greater Accuracy and Ethnically Inclusive Precision Screening

September 30, 2021
Category: iNFORMED - Blog

iCAD, Inc. recently launched ProFound AI® Risk for digital breast tomosynthesis (DBT), or 3D mammography, the world’s first commercially available clinical decision support tool that provides an accurate[1],[2] short-term breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram. The latest version of this software offers improved accuracy and enhanced functionality compared to previous versions.

 

“ProFound AI Risk has... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
PFAI_Risk_for_DBT_Blog_Image_-_2.jpg

iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography

September 29, 2021
Category: Press Releases

Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening

 

Technology provides critical, risk-adaptive solutions for clinicians facing complex screening challenges presented by the COVID-19 pandemic

 

NASHUA, N.H. – September 29, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI® Risk for digital breast tomosynthesis... Continue reading

Tags: press releases

ImageCare Centers Unveils PINK Better Mammo Service, Featuring Profound AI®, the World’s First FDA Cleared Artificial Intelligence Solution for 3D Mammography

September 16, 2021
Category: iNFORMED - Blog

ImageCare Centers recently announced it will adopt ProFound AI® for Digital Breast Tomosynthesis (DBT) throughout all of ImageCare’s mammography centers this October as part of its “PINK Better Mammo” service. ProFound AI® was the first artificial intelligence (AI) software for DBT, or 3D mammography, to be FDA cleared; the software is clinically proven to improve accuracy and efficiency for radiologists reading mammography.[i]

Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
ImageCare_Centers_1.jpg

iCAD to Host Educational Roundtable to Help Clinicians and Facilities Recover from COVID-19 Impact

September 09, 2021
Category: Press Releases

Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlog

 

NASHUA, N.H. – September 9, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host an educational roundtable event to help clinicians and their facilities recover from the impact of the COVID-19 pandemic. Titled “Pandemic Re... Continue reading

Tags: press releases

iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study

August 31, 2021
Category: Press Releases

Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months after treatment

 

NASHUA, N.H. – August 31, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and... Continue reading

Tags: press releases

iCAD Reports Financial Results for the Quarter Ended June 30, 2021

August 05, 2021
Category: Press Releases

NASHUA, N.H., Aug. 05, 2021 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2021.

Revenues for the three-mont... Continue reading

Tags: press releases

iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5

July 22, 2021
Category: Press Releases

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.


Thursday, August 5th @ 4:30pm ET

Domestic:

888-254-3590

Continue reading

Tags: press releases

Rabin Medical Center Evaluates iCAD’s ProFound AI to Improve Accuracy and Efficiency

June 28, 2021
Category: iNFORMED - Blog

Rabin Medical Center (RMC), one of the most prominent and largest medical facilities in Israel, recently initiated a clinical evaluation involving ProFound AI® for Digital Breast Tomosynthesis (DBT) at the Radiology Department at the Clalit Rabin Medical Center. Owned and operated by Clalit Health Services, RMC is Israel's largest health maintenance organization, with a capacity of 1,300 beds.

 

“The workload for radiologists had increased significantly at our facility. With an influx of tomosynthesis images to read through each d... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
Clalit_Rabin_Medical_Center.jpg

iCAD’s ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval

June 14, 2021
Category: Press Releases

iCAD’s third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations

 

NASHUA, N.H. – June 14, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis (DBT) received CE Mark approval.

Continue reading

Tags: press releases

iCAD Signs Global Distribution Agreement with Sectra

June 08, 2021
Category: Press Releases

Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide

 

 

NASHUA, N.H. – June 8th, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a worldwide distribution agreement with Sectra, an international medical imaging IT and cybersecurity company. Through this agreement, Pr... Continue reading

Tags: press releases

iCAD to Participate in Upcoming Virtual Investor Conferences

May 17, 2021
Category: Press Releases

NASHUA, N.H., May 17, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will be participating at the following three virtual investor conferences in May and June:

Oppenheimer’s MedTech, Tools & Diagnostics Summit will post a pre-recorded presentation on Wednesday, May 26, 2021. The 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 will host a l... Continue reading
Tags: press releases

iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25

May 17, 2021
Category: Press Releases

Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer

 

NASHUA, N.H. – May 17, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a virtual roundtable discussion will feature leading experts on brain cancer from around the globe sharing clinical updates on how intraoperative radiation therapy (IORT) with the Xo... Continue reading

Tags: press releases

iCAD Reports Financial Results for the First Quarter Ended March 31, 2021

April 28, 2021
Category: Press Releases

First Quarter Revenues of .6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue

 

ProFound AI ® Product Revenue Increased 34% in the First Quarter of 2021 as Compared to 2020 First Quarter with Continued Adoption of ProFound AI ® Risk Assessment

 ... Continue reading
Tags: press releases

New Research Confirms iCAD’s ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis and Improves Radiologists’ Workflow

April 27, 2021
Category: iNFORMED - Blog

New research supporting the clinical value of ProFound AI® for Digital Breast Tomosynthesis (DBT) was recently presented at the Society of Breast Imaging (SBI) Symposium, April 9-11, and at the National Consortium of Breast Centers (NCBC) Annual Interdisciplinary Breast Center Conference (NCoBC), April 16-19. Both studies demonstrate ProFound AI helps radiologists identify normal mammograms, as well as those with increased likelihood of malignancy, with greater precision.

 

At the SBI Symposium, Emily Conant, MD, Profess... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
new_research_confirms_profound_ai.jpg

iCAD to Report First Quarter 2021 Financial Results on Wednesday, April 28

April 20, 2021
Category: Press Releases

NASHUA, N.H., April 20, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28.


Wednesday April 28th @ 4:30pm ET

Domestic:

877-407-0784

Inter... Continue reading

Tags: press releases

New Research Confirms iCAD’s ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists’ Workflow

April 19, 2021
Category: Press Releases

Studies presented at two leading breast imaging conferences demonstrate ProFound AI

helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision

 

NASHUA, N.H. – April 19, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting the clinical value of ProFound AI® for Digital Breast Tomosynthesis (D... Continue reading

Tags: press releases

iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition

April 05, 2021
Category: Press Releases

Company expects preliminary estimated revenues to exceed .1 million

Successor CFO search underway


NASHUA, N.H., April 05, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the first quarter of 2021. Based on preliminary, unaudited financial information, the Company expects total revenue for the first quarter of 2021 to... Continue reading

Tags: press releases

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon